Last reviewed · How we verify
Suglat (IPRAGLIFLOZIN)
Ipragliflozin (Suglat) is a marketed SGLT2 inhibitor primarily indicated for Type 1 Diabetes Mellitus, competing in a crowded market with several other SGLT2 inhibitors. Its key strength lies in its mechanism of action, which effectively blocks glucose reabsorption in the kidneys, leading to glucose excretion in the urine. The primary risk is the impending patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | IPRAGLIFLOZIN |
|---|---|
| Target | Sodium/glucose cotransporter 2 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 2014 |
Approved indications
- Diabetes mellitus type 1
- Diabetes mellitus type 2
Common side effects
Key clinical trials
- A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Type 2 Diabetic Patients (PHASE3)
- A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic Patients (PHASE3)
- A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients (PHASE3)
- A Study to Assess the Efficacy and Safety of ASP1941 in Japanese Type 2 Diabetes Patients (PHASE3)
- A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients (PHASE3)
- A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients (PHASE3)
- A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients (PHASE3)
- A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Suglat CI brief — competitive landscape report
- Suglat updates RSS · CI watch RSS